Drug intelligence / Profile preview

ABY-062

Development stage: Preclinical
Lead developer: Affibody
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Inhalation

Overview

ABY-062 is a recombinant protein developed by Affibody AB. It is designed to target somatostatin receptor 2 (SSTR2), a receptor often expressed in neuroendocrine tumors and other SSTR2-expressing cancers, for which it is being investigated as a potential therapeutic agent. Biovian Oy is partnered with Affibody AB for the manufacturing of ABY-062 for clinical trial material production.

Other names: ABY-062-Affibody-TSLP-Affibody molecule (inhaled)

Targets

TSLP (Thymic stromal lymphopoietin)SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on ABY-062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABY-062.